Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | BCR | P11274 | 1/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.56 |
| ▸ | PRKCA | P17252 | 1/20 | 0.56 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.44 |
| ▸ | ITK | Q08881 | 3/20 | 0.43 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4245472 | 0.86 | AIMP2 (0.42) | EGFRABL1BCRSRCPRKCA | |
| SCHEMBL13911389 | 0.78 | ROCK1 (0.44) | PRKCD | |
| SCHEMBL4248784 | 0.78 | KDR (0.48) | EGFRSRC | |
| SCHEMBL4660744 | 0.77 | CDK2 (0.48) | ABL1BCRPRKCAPRKCD | |
| SCHEMBL27760699 | 0.74 | ROCK1 (0.38) | JAK3 | |
| SCHEMBL4245377 | 0.73 | RET (0.39) | JAK3 | |
| SCHEMBL4244620 | 0.73 | PTK2 (0.52) | ABL1JAK3 | |
| SCHEMBL6265857 | 0.72 | ABL1 (1.00) | EGFRABL1BCRSRCPRKCA | |
| SCHEMBL4252261 | 0.72 | CCNT1 (0.50) | — | |
| SCHEMBL4247112 | 0.72 | IKBKB (0.43) | JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069360-A1 | Organic Compounds | CARAVATTI, GIORGIO (CH) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069360-A1 | Organic Compounds | BRAF, MAP3K1, RAF1 | EGFR 169/4885ABL1 279/4885BCR 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.